Illumina spin-off Grail aims to develop $1000 or less tests for early cancer diagnosis.
Have your say in our latest poll: full patient access to genomic data. A no-brainer, or a bad idea?
Over the last few months, Genomics England have been hosting a series of seminars in London, UK for the clinical and research communities involved with the 100,000 Genomes Project. Experts from around the world have been invited to explore a diverse range of topics relating to genomic medicine, and now those presentations are available online. […]
Onramp Bioinformatics are creating use-friendly infrastructure for genomic data. CEO and Founder Tim Wesselman explains how.
Illumina accelerater announces third round of funding for genomics start ups.
Biologists met in Washington this week to discuss the scientific, medical, ethical, and governance issues associated human gene editing research.
Check out just some of the opportunities available on the Front Line Genomics Jobs Board this month
Cypher Genomics to bring their interpretation technology to bear on Human Longevity’s extensive genomics database.
Athena Vision will focus on developing UCL research into gene therapies for eye disease.
Linking over 100 hospitals and laboratories, the Swiss bioinformatics company has formed the world’s largest clinical genomics network for diagnostics.
UK Government’s Autumn Spending Review reveals £250 million investment in 100,000 Genomes Project over the next 5 years.
Mosquitoes genetically-altered to resist the malaria parasite could stop the disease spread. But the technique continues to divide the scientific community.
The International Cancer Genome Consortium have announced that 1,200 cancer whole genome sequences are now available via Amazon Web Services.
Thermo Fisher Scientific forms long-term partnership with Novartis and Pfizer to develop non-small cell cancer test to serve as companion diagnostic across drug development.
Survey finds that consumers aren’t rushing to hand over their health data to tech companies like Google, Facebook, Apple or Microsoft.